Joshua D. Thomas

Mersana Therapeutics (United States) — United States

Medicine · Health Sciences

13h-index516citations131works0.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(76), HER2/EGFR in Cancer Research(58), Synthesis and Biological Evaluation(39), interferon and immune responses(26), Neuroblastoma Research and Treatments(15)

Publications131 total

Form Follows Function: A New Paradigm of Pancreatic Cancer Progression
2025Open Access
Abstract P3-09-16: SerpinE2 mediated cell competition during breast cancer metastasis to the liver
Clinical Cancer Research·2025Open Access
Abstract PS1-01: Tumor Infiltrating Lymphocytes (TILs) as a Predictive Marker of Pathological Complete Response (pCR) in a Diverse Patient Population with Early Triple Negative Breast Cancer (TNBC) Treated with the Neoadjuvant KEYNOTE-522 Regimen
Clinical Cancer Research·2025
Supplementary Figure S3 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
2025Open Access
Supplementary Table S1 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
2025Open Access
Supplementary Figure S7 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
2025Open Access
Supplementary Figure S4 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
2025Open Access
Supplementary Figure S1 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
2025Open Access
Data from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
2025Open Access
Supplementary Table S2 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
2025Open Access
Supplementary Table S4 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
2025Open Access
Supplementary Figure S2 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
2025Open Access
Supplementary Figure S6 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
2025Open Access
Supplementary Figure S5 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
2025Open Access
Supplementary Figure S8 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
2025Open Access
Supplementary Table S3 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
2025Open Access
XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
Clinical Cancer Research·2025· 20 citedOpen Access
Patient–specific hemodynamic modeling to optimize LVAD speed and right heart health
JHLT Open·2024· 1 citedOpen Access
Endotracheal hamartoma causing persistent dyspnoea after coronary artery bypass grafting
BMJ Case Reports·2024Open Access
Figure S3 from Development of a Novel DNA Mono-alkylator Platform for Antibody–Drug Conjugates
2024Open Access
page 1 of 7Next →

Frequent Co-authors

Timothy B. Lowinger(28), LiuLiang Qin(19), Kalli C. Catcott(19), Marc Damelin(19), Dorin Toader(19), Mao Yin(18), Natalya D. Bodyak(17), Marina Protopopova(17), Eugene Kelleher(17), Elena Ter‐Ovanesyan(16), Scott D. Collins(15), Brian Jones(15), Aleksandr V. Yurkovetskiy(11), Ling Xu(11), Alex Uttard(10), Charlie Bu(10), Jeremy R. Duvall(10), Raghida A. Bukhalid(10), Damon R. Demady(10), Dmitry R. Gumerov(9)